New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Tepezza (teprotumumab-trbw) for injection, for intravenous use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

TEPEZZA is a prescription medicine. TEPEZZA used for thyroid eye disease treatment.
INDICATIONS AND USAGE
TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease
DOSAGE FORMS & STRENGTHS
For Injection: 500 mg lyophilized powder in a single-dose vial for reconstitution
Manufactured By: Horizon
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “TEPEZZA (teprotumumab-trbw) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards
It is a human monoclonal antibody developed by Genmab and Roche. It binds to IGF-1R. Teprotumumab was approved for use in the United States in January 2020.

Related Products